Lupus & antiphospholipid syndrome
Serum long non-coding Ribonucleic Acid H19 serves as a biomarker for systemic lupus erythematosus and participates in the disease progression
Authors' conclusion
The expression of H19 is upregulated in patients with SLE and plays a role in cell function and inflammation by targeting miR-19b in PBMCs, which may be one of the pathological mechanisms of SLE.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE)
- Comparison
- SLE vs controls
- Outcome
- Expression of H19 and its possible molecular mechanism in SLE
Methodological detailscase-control biomarker study, in vitro studies, H19 and miR-19b measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR); ROC analysis; Pearson correlation; flow cytometry and CCK-8; Enzyme-linked immunosorbent assay (ELISA); luciferase reporter assay
- Case-control biomarker study
- In vitro studies
- H19 and miR-19b measured by RT-qPCR; ROC analysis; Pearson correlation; flow cytometry and CCK-8; ELISA; luciferase reporter assay
Main finding
As reported in the abstract
H19 and miR-19b expression in serum and peripheral blood mononuclear cells (PBMCs)
- H19 up-regulated in SLE
- miR-19b down-regulated in SLE
- Serum H19 has certain clinical diagnostic value in SLE (ROC)
- In vitro, H19 overexpression significantly inhibits PBMC viability and promotes PBMC apoptosis and inflammatory response by interacting with miR-19b
Original publication
Serum long non-coding Ribonucleic Acid H19 serves as a biomarker for systemic lupus erythematosus and participates in the disease progression. Lupus. Published 18 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →